View as an RSS Feed
Fiscal Cliff And The Obesity Epidemic
on Dec. 26, 2012 • 4 Comments
- Will Physicians Prescribe Vivus' Qsymia?
- Pfizer's Success With Its JAK Inhibitor
- Results Of My Options Strategy For Vivus
- Another Option Strategy For Vivus
- Merck's Oral Immunotherapy For Allergic Rhino-Conjunctivitis
- The Battle For The Anti-Coagulation Market
- India's Iran Gambit: The Hunt For Oil
- Targacept Stumbles Again
- Depressing Results From Targacept's Phase III Study
- Investing In A Charlie Brown Market: Options In Leveraged ETFs
- One Way To Profit With Leveraged ETFs
- When to Buy Biotechnology Stocks?
- Earnings: What Happened to Dendreon?
- Accountable Care Organizations: The Effect on Medical Care and Healthcare-Related Stocks
- How Investors Should Play India's Troubling Demographics
- Who Will Win the Hepatitis C Market?
- Human Genome Sciences Options Prior to the FDA Decision
- Will Merck Succeed Where Pfizer Did Not?
- What Now for Egypt?
- Abbott the Only One Left in the Osteoarthritis Game
India's Contradictory Economics
on Nov. 15, 2010 • 8 Comments
- 4 Lessons From a Review of Arena Articles
- The Economic and Political Implications of Afghan Gold
- Human Genome Sciences: Tests Raise Questions About New Lupus Drug
- Eli Lilly and GlaxoSmithKline: A Tale of Two Different Pharmas
- J&J Has Success with Psoriasis Treatment
- On Investment and Optimism
- Another Positive Indication for Amgen's Denosumab
- Myriad Genetics: I Told You So
- Limited Investment Opportunities in Indian Pharmaceutical Services
- Cangene: Canada's Answer to Bioterrorism